These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28530791)

  • 21. Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected].
    Geryk-Hall M; Yang Y; Hughes DP
    Mol Cancer Ther; 2010 May; 9(5):1111-9. PubMed ID: 20406948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ras farnesyltransferase: a new therapeutic target.
    Leonard DM
    J Med Chem; 1997 Sep; 40(19):2971-90. PubMed ID: 9301658
    [No Abstract]   [Full Text] [Related]  

  • 23. Ras processing as a therapeutic target in hematologic malignancies.
    Le DT; Shannon KM
    Curr Opin Hematol; 2002 Jul; 9(4):308-15. PubMed ID: 12042705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
    Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
    Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion of protein farnesyltransferase to a geranylgeranyltransferase.
    Terry KL; Casey PJ; Beese LS
    Biochemistry; 2006 Aug; 45(32):9746-55. PubMed ID: 16893176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
    Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using inhibitors of prenylation to block localization and transforming activity.
    Berzat AC; Brady DC; Fiordalisi JJ; Cox AD
    Methods Enzymol; 2006; 407():575-97. PubMed ID: 16757354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
    Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy.
    Klochkov SG; Neganova ME; Yarla NS; Parvathaneni M; Sharma B; Tarasov VV; Barreto G; Bachurin SO; Ashraf GM; Aliev G
    Semin Cancer Biol; 2019 Jun; 56():128-134. PubMed ID: 29100957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic modulation of k-ras signaling in colorectal cancer.
    Krens LL; Baas JM; Gelderblom H; Guchelaar HJ
    Drug Discov Today; 2010 Jul; 15(13-14):502-16. PubMed ID: 20594936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Correlation between inhibitory effect of Manumycin on human hepatoma cancer cell HepG2 and Ras signal transduction pathway].
    Zhou JM; Pan QC; Yang XP; Liu ZC; Liao DF; Fu LW; Liang YJ
    Ai Zheng; 2002 Apr; 21(4):364-8. PubMed ID: 12452012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Farnesyltransferase inhibitor, manumycin a, prevents atherosclerosis development and reduces oxidative stress in apolipoprotein E-deficient mice.
    Sugita M; Sugita H; Kaneki M
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1390-5. PubMed ID: 17363690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Nat Rev Drug Discov; 2007 Jul; 6(7):541-55. PubMed ID: 17585331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions.
    Tamanoi F; Lu J
    Enzymes; 2013; 34 Pt. B():181-200. PubMed ID: 25034105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Farnesyltransferase inhibitors.
    Kurzrock R
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):161-2. PubMed ID: 16166986
    [No Abstract]   [Full Text] [Related]  

  • 36. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Aspergillus fumigatus farnesyltransferase β-subunit, RamA, mediates growth, virulence, and antifungal susceptibility.
    Norton TS; Al Abdallah Q; Hill AM; Lovingood RV; Fortwendel JR
    Virulence; 2017 Oct; 8(7):1401-1416. PubMed ID: 28489963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Staurosporines disrupt phosphatidylserine trafficking and mislocalize Ras proteins.
    Cho KJ; Park JH; Piggott AM; Salim AA; Gorfe AA; Parton RG; Capon RJ; Lacey E; Hancock JF
    J Biol Chem; 2012 Dec; 287(52):43573-84. PubMed ID: 23124205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on ras in human hepatic stellate cells.
    Carloni V; Pinzani M; Giusti S; Romanelli RG; Parola M; Bellomo G; Failli P; Hamilton AD; Sebti SM; Laffi G; Gentilini P
    Hepatology; 2000 Jan; 31(1):131-40. PubMed ID: 10613738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
    Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
    J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.